The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.
Standard
The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. / Jordan, K; Jahn, F; Jahn, P; Behlendorf, T; Stein, Alexander; Ruessel, J; Kegel, T; Schmoll, H-J.
In: BONE MARROW TRANSPL, Vol. 46, No. 6, 6, 2011, p. 784-789.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.
AU - Jordan, K
AU - Jahn, F
AU - Jahn, P
AU - Behlendorf, T
AU - Stein, Alexander
AU - Ruessel, J
AU - Kegel, T
AU - Schmoll, H-J
PY - 2011
Y1 - 2011
N2 - Complete protection from nausea/vomiting is currently achieved in a minority of patients receiving high-dose chemotherapy (HDC). Currently the use of 5-HT3-antagonists and dexamethasone (DEX) represents the standard of care. The role of the NK-1-antagonist aprepitant in HDC remains to be better defined. A total of 64 patients undergoing multiple days of HDC received granisetron, DEX plus aprepitant during chemotherapy. After the end of chemotherapy aprepitant plus DEX was given for a further 2 days. Primary end point was CR defined as no vomiting and no use of rescue medication in the overall phase (day 1 until 5 days after end of chemotherapy). Acute/delayed and overall CR were achieved in 83%/70% and 63%, respectively. Acute and delayed nausea were observed in 20 and 38% of the patients. The tolerability of the aprepitant regimen over 4-5 days was comparable with the 3-day antiemetic regimen. In our study, aprepitant demonstrated good tolerability. Taking into account the methodological constraints of comparing our results with those from the available literature, the addition of aprepitant to the antiemetic treatment regimen may provide improved prevention of chemotherapy-induced nausea and vomiting during HDC.
AB - Complete protection from nausea/vomiting is currently achieved in a minority of patients receiving high-dose chemotherapy (HDC). Currently the use of 5-HT3-antagonists and dexamethasone (DEX) represents the standard of care. The role of the NK-1-antagonist aprepitant in HDC remains to be better defined. A total of 64 patients undergoing multiple days of HDC received granisetron, DEX plus aprepitant during chemotherapy. After the end of chemotherapy aprepitant plus DEX was given for a further 2 days. Primary end point was CR defined as no vomiting and no use of rescue medication in the overall phase (day 1 until 5 days after end of chemotherapy). Acute/delayed and overall CR were achieved in 83%/70% and 63%, respectively. Acute and delayed nausea were observed in 20 and 38% of the patients. The tolerability of the aprepitant regimen over 4-5 days was comparable with the 3-day antiemetic regimen. In our study, aprepitant demonstrated good tolerability. Taking into account the methodological constraints of comparing our results with those from the available literature, the addition of aprepitant to the antiemetic treatment regimen may provide improved prevention of chemotherapy-induced nausea and vomiting during HDC.
KW - Adult
KW - Humans
KW - Male
KW - Female
KW - Middle Aged
KW - Young Adult
KW - Treatment Outcome
KW - Drug Combinations
KW - Receptors, Neurokinin-1/antagonists & inhibitors
KW - Antiemetics/therapeutic use
KW - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/therapeutic use
KW - Carboplatin
KW - Drug Toxicity
KW - Etoposide
KW - Granisetron/therapeutic use
KW - Ifosfamide
KW - Melphalan/administration & dosage/therapeutic use
KW - Morpholines/administration & dosage/therapeutic use
KW - Nausea/chemically induced/prevention & control
KW - Paclitaxel
KW - Vomiting/chemically induced/prevention & control
KW - Adult
KW - Humans
KW - Male
KW - Female
KW - Middle Aged
KW - Young Adult
KW - Treatment Outcome
KW - Drug Combinations
KW - Receptors, Neurokinin-1/antagonists & inhibitors
KW - Antiemetics/therapeutic use
KW - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/therapeutic use
KW - Carboplatin
KW - Drug Toxicity
KW - Etoposide
KW - Granisetron/therapeutic use
KW - Ifosfamide
KW - Melphalan/administration & dosage/therapeutic use
KW - Morpholines/administration & dosage/therapeutic use
KW - Nausea/chemically induced/prevention & control
KW - Paclitaxel
KW - Vomiting/chemically induced/prevention & control
M3 - SCORING: Journal article
VL - 46
SP - 784
EP - 789
JO - BONE MARROW TRANSPL
JF - BONE MARROW TRANSPL
SN - 0268-3369
IS - 6
M1 - 6
ER -
